Stocktoria
Surrozen, Inc./DE SRZN
Surrozen, Inc./DE (SRZN) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $3.5M at a -6960.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.827 |
| Retained earnings / assets | -5.341 |
| EBIT / assets | -0.426 |
| Equity / liabilities | -0.655 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SRZN | Surrozen, Inc./DE | 2/9 | -15.54 | — | -67.4% |
| CRSP | CRISPR Therapeutics AG | 1/9 | 6.42 | — | -90.6% |
| DYAI | DYADIC INTERNATIONAL INC | 1/9 | — | — | — |
| CGON | CG Oncology, Inc. | 2/9 | — | — | — |
| OCGN | Ocugen, Inc. | 2/9 | — | — | — |
| ALGS | Aligos Therapeutics, Inc. | 2/9 | — | — | — |
| HUMA | Humacyte, Inc. | 3/9 | — | — | — |
About Surrozen, Inc./DE
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
FAQ
Is SRZN financially healthy?
Surrozen, Inc./DE's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SRZN pay a dividend?
No, Surrozen, Inc./DE does not currently pay a dividend.
How profitable is SRZN?
In FY2025, Surrozen, Inc./DE had a net margin of -6960.8%.
What is the analyst price target for SRZN?
The average Wall-Street price target for Surrozen, Inc./DE is $42.50, about 75.7% above the recent price, from 4 analysts.
Is SRZN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Surrozen, Inc./DE: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.